| Name | L-Thyroxine sodium |
| Description | L-Thyroxine sodium (LT4 sodium), the major hormone derived from the thyroid gland, is the agonist of Thyroid hormone receptor alpha and beta. |
| Cell Research | Cell lines: LS180V cells. Concentrations: 100 nM and 100μM. Incubation Time: 72 h. Method: LS180V cells are induced for 72 h with two l-T4 concentrations of 100 nM and 100 μM.
|
| Animal Research | Animal Models: SD rats. Dosages: 20 μg/kg/day and 100 μg/kg/day. Administration: i.p.
|
| In vitro | evothyroxine (L-T(4))can upregulate the expression of P-gp mRNA and protein in LS180 cells, but only L-T(4) and L-T(3) can produce the same effect in Caco-2 cells, which are relatively lacking in PXR[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (2.5 mM), Sonication is recommended.
DMSO : 27.5 mg/mL (34.42 mM), Sonication is recommended.
|
| Keywords | Thyroidhormonereceptor(THR) | Thyroidhormonereceptor | Thyroid hormone receptor(THR) | Thyroid hormone receptor | Thyroid Hormone Receptor | Thyroid Hormone | THR | T-4 | T 4 | L-Thyroxine sodium | LThyroxine sodium | L-Thyroxine | Levothyroxine | L Thyroxine sodium | Inhibitor | inhibit |
| Inhibitors Related | Sucrose | Aceglutamide | Emtricitabine | 3-Hydroxybutyric acid sodium | Levulinic acid | D(+)-Raffinose pentahydrate | D-(+)-Trehalose dihydrate | Glycerol | Thymidine | Sodium 2-hydroxybutanoate | Chitosan oligosaccharide | 3-Indoleacetic acid |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | Pediatric Drug Library | Drug Repurposing Compound Library | NO PAINS Compound Library | FDA-Approved Drug Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library |
United States
